You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Yellow Fever Vaccine for a Vulnerable Population

    SBC: NAJIT TECHNOLOGIES INC            Topic: NIAID

    ABSTRACT Yellow fever virus (YFV) represents a mosquito-borne emerging/re-emerging human pathogen that causes 20- 50% mortality and is endemic in andgt;40 countries. The current live attenuated YFV vaccine was developed in 1936 and following the establishment of a virus seed lot system, it has not been modified or otherwise improved in over 50 years. According to the CDC, this vaccine causes 47 se ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    ABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Factor XI inhibitor for thrombosis

    SBC: ARONORA INC            Topic: NHLBI

    Project Summary Although potent antithrombotic agents are availableall of these drugs inadvertently target vital hemostatic molecular mechanismsresulting in dose limiting hemorrhagic toxicity that restrict their useDue to a lack of safe thromboprophylaxisthrombotic blood vessel occlusions continue to be extremely prevalentand result in a wide range of severe disease conditions that remain the lead ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Immersive Virtual Reality as a Tool to Improve Police Safety in Adolescents and Adults with ASD

    SBC: Floreo, Inc.            Topic: 103

    Floreo Technology proposes to develop the Police Safety Module (PSM), an innovative, immersive mobile virtual reality (VR) application designed to train police safety in adolescents and adults with autism spectrum disorder (ASD). ASD has been increasing in prevalence over recent years. While much attention has been paid to the causes and early diagnosis of ASD, there remains a clear need for effec ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Large Pore SPP Particles for Protein Separations

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B

    SBC: TOMEGAVAX, INC.            Topic: R

    Abstract Although an efficient prophylactic vaccine is available for hepatitis B virusHBVchronic hepatitis BCHBaffects up tomillion people worldwideand despite advances remains mostly incurableIn adultsacute HBV infection is cleared inof cases by CDT cell mediated mechanismsbut chroniclifelong infection ensues in the remaining individualswhich can lead to liver cirrhosis and cancerThe induction an ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government